Baxter Bros Inc. Buys New Stake in Boston Scientific Co. (NYSE:BSX)

Baxter Bros Inc. purchased a new position in Boston Scientific Co. (NYSE:BSX) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 4,012 shares of the medical equipment provider’s stock, valued at approximately $232,000.

Other large investors have also made changes to their positions in the company. BSW Wealth Partners increased its holdings in shares of Boston Scientific by 2.3% in the fourth quarter. BSW Wealth Partners now owns 7,398 shares of the medical equipment provider’s stock valued at $428,000 after purchasing an additional 165 shares during the period. Valley National Advisers Inc. raised its position in shares of Boston Scientific by 2.3% in the fourth quarter. Valley National Advisers Inc. now owns 7,526 shares of the medical equipment provider’s stock worth $435,000 after acquiring an additional 170 shares during the period. Aveo Capital Partners LLC grew its position in shares of Boston Scientific by 1.3% during the 4th quarter. Aveo Capital Partners LLC now owns 12,841 shares of the medical equipment provider’s stock valued at $742,000 after acquiring an additional 171 shares during the period. Whitaker Myers Wealth Managers LTD. raised its holdings in Boston Scientific by 4.6% in the 4th quarter. Whitaker Myers Wealth Managers LTD. now owns 4,093 shares of the medical equipment provider’s stock worth $237,000 after purchasing an additional 179 shares during the period. Finally, Brighton Jones LLC grew its holdings in Boston Scientific by 5.4% in the third quarter. Brighton Jones LLC now owns 3,999 shares of the medical equipment provider’s stock valued at $211,000 after purchasing an additional 205 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In related news, Director Edward J. Ludwig sold 9,818 shares of the business’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $73.29, for a total value of $719,561.22. Following the completion of the sale, the director now directly owns 41,374 shares of the company’s stock, valued at $3,032,300.46. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Director Edward J. Ludwig sold 9,818 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $73.29, for a total transaction of $719,561.22. Following the transaction, the director now directly owns 41,374 shares in the company, valued at $3,032,300.46. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP John Bradley Sorenson sold 17,587 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $71.50, for a total transaction of $1,257,470.50. Following the completion of the sale, the executive vice president now directly owns 50,638 shares of the company’s stock, valued at $3,620,617. The disclosure for this sale can be found here. Insiders have sold 78,384 shares of company stock valued at $5,395,560 in the last ninety days. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 1.1 %

Shares of NYSE BSX traded up $0.82 during mid-day trading on Friday, hitting $72.85. The company had a trading volume of 7,452,084 shares, compared to its average volume of 7,241,391. The business’s 50-day simple moving average is $68.42 and its 200 day simple moving average is $61.27. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 0.82. The company has a market capitalization of $106.88 billion, a PE ratio of 61.22, a price-to-earnings-growth ratio of 2.48 and a beta of 0.77. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $74.39.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. The business had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. During the same quarter in the prior year, the business posted $0.45 EPS. On average, analysts predict that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Needham & Company LLC boosted their price objective on Boston Scientific from $71.00 to $82.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. TD Cowen increased their price objective on Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research note on Thursday, March 7th. Robert W. Baird lifted their target price on shares of Boston Scientific from $79.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday, April 25th. Finally, Royal Bank of Canada raised their price target on shares of Boston Scientific from $78.00 to $82.00 and gave the stock an “outperform” rating in a research note on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $75.09.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.